News

Mr Kogod currently serves as DaVita’s president-west, a role he has occupied since October 2005. Mr Mello, who served as COO since June 2000, will continue with the

Alcon Research Limited (ARL) is an affiliate of Alcon Inc, an eye care company. The alliance combines Origenis’s capabilities in compound design, chemical synthesis, and screening with Alcon’s

The NXL103 Phase II study was a double-blind, multinational, randomized, comparative study that evaluated this oral antibacterial as a treatment for mild to moderate community acquired pneumonia. The

On a pro forma non-GAAP basis, the company recorded net income of $1.13 billion, or $1.04 per share in the third quarter of 2008, compared with third-quarter 2007

The Phase I clinical trial was designed to assess the safety, pharmacokinetics and pharmacodynamics of carfilzomib among patients with advanced solid tumors who had previously failed at least

Ms Fiumenero joined Vitae in January 2006 as senior vice president of finance and administration. Prior to joining Vitae Pharmaceuticals, Ms Fiumenero has spent 13 years at Bristol-Myers

The Phase II clinical trial is an open-label, dose-escalating pharmacokinetic, pharmacodynamic, efficacy and safety study of CTA018 injection in chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT)

The agreement covers the existing 301 Velocity Way building of approximately 163,000sqft and approximately 30 acres designed to accommodate up to an additional 542,000sqft of office space. Gilead

The company said that it plans to launch the product immediately in the US market. The carotid Wallstent is a self-expanding stent mounted on a rapid exchange delivery